Literature DB >> 12032390

Mifepristone: contraceptive and non-contraceptive uses.

Pak Chung Ho1, Ernest Hung Yu Ng, Oi Shan Tang.   

Abstract

Mifepristone is an orally active progesterone antagonist. It can be used for both contraceptive and non-contraceptive clinical indications. It is a very effective drug for emergency contraception with a low incidence of side effects. There is a potential for mifepristone to be used as a once-a-month pill. There is a need, however, for a simple, inexpensive and accurate method to identify the luteinizing hormone surge before this method can be used in clinical practice. The daily administration of mifepristone offers promise as an effective method of contraception but more studies need to be done. The combination of mifepristone with a prostaglandin analogue is a well-established method for termination of pregnancy of up to 9 weeks. Recent data suggest that this combination may also be used up to 9-13 weeks of pregnancy. Although mifepristone is effective in dilating the cervix before vacuum aspiration, misoprostol is probably the drug of choice in most situations. In the second trimester, mifepristone is effective in shortening the abortion process induced by prostaglandin analogues. The combination of mifepristone and prostaglandin also offers a medical method for management of miscarriages. Mifepristone has been used for a number of other indications, but further studies are needed before such treatment can be recommended.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032390     DOI: 10.1097/00001703-200206000-00013

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  4 in total

1.  Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.

Authors:  Alicia A Goyeneche; Rubén W Carón; Carlos M Telleria
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

2.  Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression.

Authors:  Donata Ponikwicka-Tyszko; Marcin Chrusciel; Joanna Stelmaszewska; Piotr Bernaczyk; Paulina Chrusciel; Maria Sztachelska; Mika Scheinin; Mariusz Bidzinski; Jacek Szamatowicz; Ilpo T Huhtaniemi; Slawomir Wolczynski; Nafis A Rahman
Journal:  EBioMedicine       Date:  2019-08-26       Impact factor: 8.143

3.  Application of an in Vitro Assay to Identify Chemicals That Increase Estradiol and Progesterone Synthesis and Are Potential Breast Cancer Risk Factors.

Authors:  Bethsaida Cardona; Ruthann A Rudel
Journal:  Environ Health Perspect       Date:  2021-07-21       Impact factor: 9.031

4.  Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway.

Authors:  Jingwei Shao; Guirong Zheng; Hongning Chen; Jian Liu; Aixiao Xu; Fan Chen; Tao Li; Yusheng Lu; Jianguo Xu; Ning Zheng; Lee Jia
Journal:  Oncotarget       Date:  2017-06-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.